Summary
Alnylam Pharmaceuticals, Inc. (ALNY) announced on November 14, 2017, the pricing of a public offering of its common stock. The company entered into an underwriting agreement to sell approximately 5.6 million shares at a public offering price of $125.00 per share. This offering is expected to generate substantial gross proceeds for the company, with net proceeds estimated to be around $682.1 million, before considering any potential exercise of the underwriters' option to purchase additional shares. The proceeds from this offering are intended to strengthen Alnylam's financial position and support its ongoing research and development activities, including advancing its pipeline of RNAi therapeutics. The offering utilizes an existing shelf registration statement and is expected to close around November 16, 2017, marking a significant capital raise event for the company.
Key Highlights
- 1Alnylam Pharmaceuticals priced a public offering of 5,600,000 shares of common stock.
- 2The offering price is set at $125.00 per share.
- 3The company expects to receive net proceeds of approximately $682.1 million from the offering.
- 4An option was granted to underwriters to purchase up to an additional 840,000 shares.
- 5The offering is being conducted through an underwritten public offering under an existing shelf registration statement.
- 6The underwriting agreement was entered into with Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC as representatives of the underwriters.
- 7The offering is expected to close on November 16, 2017.